Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

Written By Lara Wilson

Deng M. et al. 2021. Antibody Therapeutics. 4(1):16-33.

Lara Wilson
Previous

LILRB3 supports acute myeloid leukemia development and regulates T-cell antitumor immune responses through the TRAF2–cFLIP–NF-κB signaling axis
Next

Antagonistic Antibodies Targeting LAIR1 Enhance T Lymphocyte Activation and Promote Inflammatory Phenotypes in Myeloid Cells